Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78years of age

British Journal of Haematology

Volumn 153, Issue 1, 2011, Pages 76-82

  Samuelson, Scott ^a   Sandmaier, Brenda M ^b   Heslop, Helen E ^c   Popat, Uday ^d   Carrum, George ^c   Champlin, Richard E ^d   Storb, Rainer ^b   Prchal, Josef T ^a   Gooley, Theodore A ^b   Joachim Deeg, H ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Haematopoietic cell transplantation; Myelofibrosis; Older patients

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD45; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD DONOR; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENGRAFTMENT; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; MORTALITY; MYELOFIBROSIS; MYELOID METAPLASIA; OVERALL SURVIVAL; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SIBLING; THROMBOTIC THROMBOCYTOPENIC PURPURA; WHOLE BODY RADIATION;

AGE FACTORS; AGED; EPIDEMIOLOGIC METHODS; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; PRIMARY MYELOFIBROSIS; RECURRENCE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 79952609641     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08582.x     Document Type: Article

References (30)

1. Ballen, K.K., Shrestha, S., Sobocinski, K.A., Zhang, M.J., Bashey, A., Bolwell, B.J., Cervantes, F., Devine, S.M., Gale, R.P., Gupta, V., Hahn, T.E., Hogan, W.J., Kroger, N., Litzow, M.R., Marks, D.I., Maziarz, R.T., McCarthy, P.L., Schiller, G., Schouten, H.C., Roy, V., Wiernik, P.H., Horowitz, M.M., Giralt, S.A. & Arora, M. (2010) Outcome of transplantation for myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 358-367.
2. Benesch, M. & Deeg, H.J. (2008) Acute graft-versus-host disease. In: Hematopoietic Stem Cell Transplantation (ed. by R.J. Soiffer ), p. 589. Humana Press, Totowa, NJ.
3. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895-2901.
4. Ciurea, S.O., de Lima, M., Giralt, S., Saliba, R., Bueso-Ramos, C., Andersson, B.S., Hosing, C.M., Verstovsek, S., Champlin, R.E. & Popat, U. (2010) Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biology of Blood and Marrow Transplantation, 16, 555-559.
5. Deeg, H.J., Gooley, T.A., Flowers, M.E.D., Sale, G.E., Slattery, J.T., Anasetti, C., Chauncey, T.R., Doney, K., Georges, G.E., Kiem, H.-P., Martin, P.J., Petersdorf, E.W., Radich, J., Sanders, J.E., Sandmaier, B.M., Warren, E.H., Witherspoon, R.P., Storb, R. & Appelbaum, F.R. (2003) Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood, 102, 3912-3918.
6. Devine, S.M., Hoffman, R., Verma, A., Shah, R., Bradlow, B.A., Stock, W., Maynard, V., Jessop, E., Peace, D., Huml, M., Thomason, D., Chen, Y.-H. & van Besien, K. (2002) Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. Blood, 99, 2255-2258.
7. Eissa, H., Gooley, T.A., Sorror, M.L., Nguyen, F., Scott, B.L., Doney, K., Loeb, K.R., Martin, P.J., Pagel, J.M., Radich, J.P., Sandmaier, B.M., Warren, E.H., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2010) Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities. Biology of Blood and Marrow Transplantation, prepublished online September 26, 2010; doi:.
8. Filipovich, A.H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J.R., Lee, S.J., Martin, P., Chien, J., Prezepiorka, D., Couriel, D., Cowen, E.W., Dinndorf, P., Farrell, A., Hartzman, R., Henslee-Downey, J., Jacobsohn, D., McDonald, G., Mittleman, B., Rizzo, J.D., Robinson, M., Schubert, M., Schultz, K., Shulman, H., Turner, M., Vogelsang, G. & Flowers, M.E.D. (2005) National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report. Biology of Blood and Marrow Transplantation, 11, 945-956.
9. Flowers, M.E.D., Storer, B.E., Lee, S.J., Campregher, P.V., Vigorito, A.C., Carpenter, P.A., Mielcarek, M., Appelbaum, F.R. & Martin, P.J. (2009) Risk factors for the development of acute and National Institute of Health (NIH) chronic graft-versus-host disease (GVHD). Blood (ASH Annual Meeting Abstracts), 114, 146. Abstract 345.
10. Giaccone, L., McCune, J.S., Maris, M.B., Gooley, T.A., Sandmaier, B.M., Slattery, J.T., Cole, S., Nash, R.A., Storb, R. & Georges, G.E. (2005) Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood, 106, 4381-4388.
11. Hessling, J., Kroger, N., Werner, M., Zabelina, T., Hansen, A., Kordes, U., Ayuk, F.A., Renges, H., Panse, J., Erttmann, R. & Zander, A.R. (2002) Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia. British Journal of Haematology, 119, 769-772.
12. Kerbauy, D.M.B., Gooley, T.A., Sale, G.E., Flowers, M.E.D., Doney, K.C., Georges, G.E., Greene, J.E., Linenberger, M., Petersdorf, E., Sandmaier, B.M., Scott, B.L., Sorror, M., Stirewalt, D.L., Stewart, M., Witherspoon, R.P., Storb, R., Appelbaum, F.R. & Deeg, H.J. (2007) Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biology of Blood and Marrow Transplantation, 13, 355-365.
13. Kroger, N., Badbaran, A., Holler, E., Hahn, J., Kobbe, G., Bornhauser, M., Reiter, A., Zabelina, T., Zander, A.R. & Fehse, B. (2007a) Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood, 109, 1316-1321.
14. Kroger, N., Thiele, J., Zander, A., Schwerdtfeger, R., Kobbe, G., Bornhauser, M., Bethge, W., Schubert, J., de Witte, T. & Kvasnicka, H.M. (2007b) Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis. Experimental Hematology, 35, 1719-1722.
15. Kröger, N., Holler, E., Kobbe, G., Bornhauser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., Wandt, H., Burchert, A., Corradini, P., Schubert, J., Kaufmann, M., Dreger, P., Wulf, G.G., Einsele, H., Zabelina, T., Kvasnicka, H.M., Thiele, J., Brand, R., Zander, A.R., Niederwieser, D. & de Witte, T.M. (2009) Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood, 114, 5264-5270.
16. Laport, G.G., Sandmaier, B.M., Storer, B.E., Scott, B.L., Stuart, M.J., Lange, T., Maris, M.B., Agura, E.D., Chauncey, T.R., Wong, R.M., Forman, S.J., Petersen, F.B., Wade, J.C., Epner, E., Bruno, B., Bethge, W.A., Curtin, P.T., Maloney, D.G., Blume, K.G. & Storb, R.F. (2008) Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biology of Blood and Marrow Transplantation, 14, 246-255.
17. de Lima, M., Couriel, D., Thall, P.F., Wang, X., Madden, T., Jones, R., Shpall, E.J., Shahjahan, M., Pierre, B., Giralt, S., Korbling, M., Russell, J.A., Champlin, R.E. & Andersson, B.S. (2004) Once-daily intravenous buslfan and fludarabine: clinical and pharmacokinetic results of a myeloabltive, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood, 104, 857-864.
18. Martin, P., Nash, R., Sanders, J., Leisenring, W., Anasetti, C., Deeg, H.J., Storb, R. & Appelbaum, F. (1998) Reproducibility in retrospective grading of acute graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplantation, 21, 273-279.
19. Mesa, R.A., Verstovsek, S., Kantarjian, H.M., Pardanani, A.D., Friedman, S., Newton, R., Erickson-Viitanen, S., Hunter, D., Redman, J., Yeleswaram, S., Bradley, E. & Tefferi, A. (2008) INCB018424, a selective JAK1/2 inhibitor, significantly improves the compromised nutritional status and frank cachexia in patients with myelofibrosis (MF). Blood (ASH Annual Meeting Abstracts), 112, 621-622. Abstract 1760.
20. Oran, B., Giralt, S., Saliba, R., Hosing, C., Popat, U., Khouri, I., Couriel, D., Qazilbash, M., Anderlini, P., Kebriaei, P., Ghosh, S., Carrasco-Yalan, A., de Meis, E., Anagnostopoulos, A., Donato, M., Champlin, R.E. & de Lima, M. (2007) Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan. Biology of Blood and Marrow Transplantation, 13, 454-462.
21. Petersdorf, E.W., Gooley, T.A., Anasetti, C., Martin, P.J., Smith, A.G., Mickelson, E.M., Woolfrey, A.E. & Hansen, J.A. (1998) Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood, 92, 3515-3520.
22. Popat, U., Carrum, G., May, R., Lamba, R., Krance, R.A., Heslop, H.E. & Brenner, M.K. (2005) CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donors. Bone Marrow Transplantation, 35, 1127-1132.
23. Popat, U., Heslop, H.E., Durett, A., May, R., Krance, R.A., Brenner, M.K. & Carrum, G. (2006) Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML). Bone Marrow Transplantation, 37, 547-552.
24. Rondelli, D., Barosi, G., Bacigalupo, A., Prchal, J.T., Popat, U., Alessandrino, E.P., Spivak, J.L., Smith, B.D., Klingemann, H.G., Fruchtman, S. & Hoffman, R. (2005) Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood, 105, 4115-4119.
25. Sale, G.E., Deeg, H.J. & Porter, B.A. (2006) Regression of myelofibrosis and osteosclerosis following hematopoietic cell transplantation assessed by magnetic resonance imaging and histologic grading. Biology of Blood and Marrow Transplantation, 12, 1285-1294.
26. Snyder, D.S., Palmer, J., Stein, A.S., Pullarkat, V., Sahebi, F., Cohen, S., Vora, N., Gaal, K., Nakamura, R. & Forman, S.J. (2006) Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biology of Blood and Marrow Transplantation, 12, 1161-1168.
27. Snyder, D.S., Palmer, J., Gaal, K., Stein, A.S., Pullarkat, V., Sahebi, F., Vora, N., Nakamura, R. & Forman, S.J. (2010) Improved outcomes using tacrolimus/sirolimus for graft-versus-host disease prophylaxis with a reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplant as treatment of myelofibrosis. Biology of Blood and Marrow Transplantation, 16, 281-286.
28. Sorror, M.L., Maris, M.B., Storb, R.F., Baron, F., Sandmaier, B.M., Maloney, D.G. & Barry, S.E. (2005) Hematopoietic cell transplantation (HCT)-specific-comorbidity index: a new tool for risk assessment before allogeneic HCT. Biology of Blood and Marrow Transplantation, 11(Suppl. 1), 23-24. Abstract 67.
29. Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H.M., Barbui, T., Hanson, C.A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., Reilly, J.T., Gisslinger, H., Vannucchi, A.M., Cervantes, F., Finazzi, G., Hoffman, R., Gilliland, D.G., Bloomfield, C.D. & Vardiman, J.W. (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood, 110, 1092-1097.
30. Verstovsek, S., Kantarjian, H., Mesa, R.A., Pardanani, A.D., Cortes-Franco, J., Thomas, D.A., Estrov, Z., Fridman, J.S., Bradley, E.C., Erickson-Viitanen, S., Vaddi, K., Levy, R. & Tefferi, A. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. New England Journal of Medicine, 363, 1117-1127.